IMJUDO is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Tremelimumab.
| Product ID | 0310-4505_6690679c-be2f-4588-a2e4-89fff74dd6be |
| NDC | 0310-4505 |
| Product Type | Human Prescription Drug |
| Proprietary Name | IMJUDO |
| Generic Name | Tremelimumab |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2022-10-21 |
| Marketing Category | BLA / |
| Application Number | BLA761289 |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Substance Name | TREMELIMUMAB |
| Active Ingredient Strength | 25 mg/1.25mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2022-10-21 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0310-4505 | IMJUDO | tremelimumab |
| 0310-4535 | IMJUDO | tremelimumab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() IMJUDO 90769621 not registered Live/Pending |
AstraZeneca AB 2021-06-11 |
![]() IMJUDO 86484935 5131050 Live/Registered |
AstraZeneca AB 2014-12-18 |